Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

Bibliography

• Lublin H, Haug HJ, Koponen H, Ziprasidone versus olanzapine, risperidone or quetiapine in patients chronic schizophrenia: a 12-week open-label, multicentre clinical trial. World J Biol Psychiatry 2009;10(4 Pt 3):710-18
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123(2-3):225-33
   PubMed Web of Science ®Google Scholar
• Bowden CL, Grunze H, Mullen J, A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66(1):111-21
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord 2009;11(Suppl 2):45-54
   PubMedGoogle Scholar
• Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011;24(1):10-17
   PubMed Web of Science ®Google Scholar
• Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 2010;12(2):116-41
   PubMed Web of Science ®Google Scholar
• Komossa K, Depping AM, Gaudchau A, Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010(12):CD008121
   Google Scholar
• Leucht S, Corves C, Arbter D, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41
   PubMed Web of Science ®Google Scholar
• Holt RI, Abdelrahman T, Hirsch M, The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J Psychopharmacol 2010;24(6):867-73
   PubMed Web of Science ®Google Scholar
• Bellivier F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry 2005;20(Suppl 4):S335-9
   Google Scholar
• Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 2005;19(6 Suppl):47-55
   PubMedGoogle Scholar
• Hasnain M, Vieweg WV, Fredrickson SK, Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes 2009;3(1):5-15
   PubMedGoogle Scholar
• Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119(1):4-14
   PubMed Web of Science ®Google Scholar
• Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness. BMJ 2001;322(7284):443-4
   PubMed Web of Science ®Google Scholar
• Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry 2007;164(3):402-8
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511-18
   PubMed Web of Science ®Google Scholar
• Chacon F, Mora F, Gervas-Rios A, Gilaberte I. Efficacy of lifestyle interventions in physical health management of patients with severe mental illness. Ann Gen Psychiatry 2011;10:22
   PubMedGoogle Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics : differential risk and clinical implications. CNS Drugs 2007;21(11):911-36
   PubMed Web of Science ®Google Scholar
• Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119(3):171-9
   PubMed Web of Science ®Google Scholar
• De Hert M, Cohen D, Bobes J, Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10(2):138-51
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8(2):114-26
   PubMed Web of Science ®Google Scholar
• Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005;19(6 Suppl):16-27
   PubMedGoogle Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96
   PubMed Web of Science ®Google Scholar
• De Hert M, Dobbelaere M, Sheridan EM, Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011;26(3):144-58
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51(8):480-91
   PubMed Web of Science ®Google Scholar
• Cavazzoni PA, Berg PH, Kryzhanovskaya LA, Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006;67(1):107-13
   PubMed Web of Science ®Google Scholar
• Balestrieri M, Vampini C, Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol 2000;15(7):499-512
   PubMed Web of Science ®Google Scholar
• Leucht S, Arbter D, Engel RR, How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009;14(4):429-47
   PubMed Web of Science ®Google Scholar
• Miller CH, Mohr F, Umbricht D, The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59(2):69-75
   PubMed Web of Science ®Google Scholar
• Kane JM, Fleischhacker WW, Hansen L, Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70(5):627-43
   PubMed Web of Science ®Google Scholar
• Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004;65(Suppl 9):16-20
   PubMed Web of Science ®Google Scholar
• Muscettola G, Barbato G, Pampallona S, Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999;19(3):203-8
   PubMed Web of Science ®Google Scholar
• Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006;163(8):1438-40
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Ganocy SJ, Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28(2):203-9
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 1988;145(11):1455-6
   PubMed Web of Science ®Google Scholar
• McDonald C, Bullmore ET, Sham PC, Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch Gen Psychiatry 2004;61(10):974-84
   PubMed Web of Science ®Google Scholar
• Muir WJ, Thomson ML, McKeon P, Markers close to the dopamine D5 receptor gene (DRD5) show significant association with schizophrenia but not bipolar disorder. Am J Med Genet 2001;105(2):152-8
   PubMed Web of Science ®Google Scholar
• Murray RM, Sham P, Van Os J, A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res 2004;71(2-3):405-16
   PubMed Web of Science ®Google Scholar
• Huang J, Perlis RH, Lee PH, Cross-disorder genome-wide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry 2010;167(10):1254-63
   PubMed Web of Science ®Google Scholar
• Park N, Juo SH, Cheng R, Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol Psychiatry 2004;9(12):1091-9
   PubMed Web of Science ®Google Scholar
• Peerbooms OL, van Os J, Drukker M, Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: Evidence for a common genetic vulnerability? Brain Behav Immun 2011;25(8):1530-43 Epub 2010.
   PubMed Web of Science ®Google Scholar
• Purcell SM, Wray NR, Stone JL, Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460(7256):748-52
   PubMed Web of Science ®Google Scholar
• van Winkel R, van Os J, Celic I, Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008;69(8):1319-27
   PubMed Web of Science ®Google Scholar
• Moteshafi H, Zhornitsky S, Brunelle S, Stip E. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Safety 2012; In press
   PubMedGoogle Scholar
• Stip E, Lungu OV, Anselmo K, Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry 2012;2:e128
   PubMed Web of Science ®Google Scholar
• Lungu O, Anselmo K, Letourneau G, Neuronal correlates of appetite regulation in patients with schizophrenia: Is there a basis for future appetite dysfunction? Eur Psychiatry 2012. In Press, Corrected Proof.
   PubMed Web of Science ®Google Scholar
• Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis [Computer software version 2.2.057]. 2.2.057 ed. Biostat, Englewood; NJ: 2010
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42(4):233-46
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64(5):598-604
   PubMed Web of Science ®Google Scholar
• Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996;16(2):158-69
   PubMed Web of Science ®Google Scholar
• Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res 2004;66(2-3):143-50
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL, Nelson MW, Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol 2005;28(4):163-8
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30(1):95-105
   PubMed Web of Science ®Google Scholar
• Kahn RS, Schulz SC, Palazov VD, Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(6):832-42
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Brown D, Liu S, The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull 2008;41(3):11-35
   PubMed Web of Science ®Google Scholar
• Peuskens J, Trivedi J, Malyarov S, Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont) 2007;4(11):34-50
   PubMedGoogle Scholar
• Riedel M, Muller N, Spellmann I, Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007;257(7):402-12
   PubMed Web of Science ®Google Scholar
• Riedel M, Muller N, Strassnig M, Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2005;255(6):432-7
   PubMed Web of Science ®Google Scholar
• Sirota P, Pannet I, Koren A, Tchernichovsky E. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Hum Psychopharmacol 2006;21(4):227-34
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54(6):549-57
   PubMed Web of Science ®Google Scholar
• Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006;67(7):1093-103
   PubMed Web of Science ®Google Scholar
• Chrzanowski WK, Marcus RN, Torbeyns A, Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189(2):259-66
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Marcus RN, Hardy SA, The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006;11(9):691-702; quiz 19
   PubMed Web of Science ®Google Scholar
• Kane JM, Meltzer HY, Carson WH Jr, Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68(2):213-23
   PubMed Web of Science ®Google Scholar
• Kane JM, Osuntokun O, Kryzhanovskaya LA, A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009;70(4):572-81
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6(4):325-37
   PubMed Web of Science ®Google Scholar
• Kerwin R, Millet B, Herman E, A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007;22(7):433-43
   PubMed Web of Science ®Google Scholar
• Kolotkin RL, Corey-Lisle PK, Crosby RD, Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. Eur Psychiatry 2008;23(8):561-6
   PubMed Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R, A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(Suppl 18):47-56
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64(9):1048-56
   PubMed Web of Science ®Google Scholar
• Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17(5):207-15
   PubMed Web of Science ®Google Scholar
• Breier A, Berg PH, Thakore JH, Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162(10):1879-87
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Kalali AH, Weiden PJ, Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-8
   PubMed Web of Science ®Google Scholar
• Hirsch SR, Kissling W, Bauml J, A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63(6):516-23
   PubMed Web of Science ®Google Scholar
• Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2006;21(1):21-8
   PubMed Web of Science ®Google Scholar
• é OliJP, Spina E, Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol 2006;21(3):143-51
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Galluzzo A, Valsecchi P, Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 2009;110(1-3):80-9
   PubMed Web of Science ®Google Scholar
• Azorin JM, Spiegel R, Remington G, A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001;Aug158(8):1305-13
   PubMed Web of Science ®Google Scholar
• Bondolfi G, Dufour H, Patris M, Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155(4):499-504
   PubMed Web of Science ®Google Scholar
• Dollfus S, Olivier V, Chabot B, Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res 2005;78(2-3):157-9
   PubMed Web of Science ®Google Scholar
• Hwang TJ, Lee SM, Sun HJ, Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. J Formos Med Assoc 2003;102(1):30-6
   PubMed Web of Science ®Google Scholar
• Lin CH, Kuo CC, Chou LS, A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol 2010;30(5):518-25
   PubMed Web of Science ®Google Scholar
• Peuskens J, Bech P, Moller HJ, Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 1999;88(2):107-17
   PubMed Web of Science ®Google Scholar
• Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry 2007;68(11):1793-8
   PubMed Web of Science ®Google Scholar
• Sechter D, Peuskens J, Fleurot O, Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002;Dec27(6):1071-81
   PubMed Web of Science ®Google Scholar
• Yang J, Bahk WM, Cho HS, Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol 2010;33(4):169-75
   PubMed Web of Science ®Google Scholar
• Altamura AC, Salvadori D, Madaro D, Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. J Affect Disord 2003;76(1-3):267-71
   PubMed Web of Science ®Google Scholar
• Bortnick B, El-Khalili N, Banov M, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011;128(1-2):83-94
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162(7):1351-60
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Montgomery SA, Feifel D, Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009;70(4):526-39
   PubMed Web of Science ®Google Scholar
• Endicott J, Paulsson B, Gustafsson U, Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord 2008;111(2-3):306-19
   PubMed Web of Science ®Google Scholar
• Langosch JM, Drieling T, Biedermann NC, Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. J Clin Psychopharmacol 2008;28(5):555-60
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Lam RW, Lepola U, Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 2010;27(10):964-76
   PubMed Web of Science ®Google Scholar
• McElroy SL, Martens BE, Winstanley EL, Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. J Affect Disord 2010;124(1-2):157-63
   PubMed Web of Science ®Google Scholar
• McElroy SL, Weisler RH, Chang W, A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010;71(2):163-74
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Brecher M, Paulsson B, Quetiapine or haloperidol as monotherapy for bipolar mania–a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15(5):573-85
   PubMed Web of Science ®Google Scholar
• Suppes T, Datto C, Minkwitz M, Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010;121(1-2):106-15
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH, Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26(6):600-9
   PubMed Web of Science ®Google Scholar
• Vieta E, Calabrese JR, Goikolea JM, Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007;9(4):413-25
   PubMed Web of Science ®Google Scholar
• Weisler R, Joyce M, McGill L, Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009;14(6):299-313
   PubMed Web of Science ®Google Scholar
• Young AH, McElroy SL, Bauer M, A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71(2):150-62
   PubMed Web of Science ®Google Scholar
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. [ClinicalTrials.gov identifier CN138-096*]. BRISTOL-MYERS SQUIBB 2011.
   Google Scholar
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. [ClinicalTrials.gov identifier CN138-146*]. BRISTOL-MYERS SQUIBB. 2011.
   Google Scholar
• El Mallakh RS, Vieta E, Rollin L, A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). Eur Neuropsychopharmacol 2010;20(11):776-83
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Calabrese JR, McQuade RD, A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67(4):626-37
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Marcus R, Tourkodimitris S, A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160(9):1651-8
   PubMed Web of Science ®Google Scholar
• Kemp DE, Calabrese JR, Tran QV, Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;71(9):1138-44
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20(4):536-46
   PubMed Web of Science ®Google Scholar
• Vieta E, Bourin M, Sanchez R, Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235-42
   PubMed Web of Science ®Google Scholar
• Young AH, Oren DA, Lowy A, Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009;194(1):40-8
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Versiani M, Potkin S, Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160(4):741
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Versiani M, Warrington L, Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. J Clin Psychiatry 2009;70(6):844-51
   PubMed Web of Science ®Google Scholar
• Potkin SG, Keck PE Jr, Segal S, Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25(4):301-10
   PubMed Web of Science ®Google Scholar
• Vieta E, Ramey T, Keller D, Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol 2010;24(4):547-58
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Keck PE Jr, Kramer M, Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161(6):1057-65
   PubMed Web of Science ®Google Scholar
• Khanna S, Vieta E, Lyons B, Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005;187:229-34
   PubMed Web of Science ®Google Scholar
• Muller-Siecheneder F, Muller MJ, Hillert A, Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998;18(2):111-20
   PubMed Web of Science ®Google Scholar
• Smulevich AB, Khanna S, Eerdekens M, Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005;15(1):75-84
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Potvin S, Moteshafi H, Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol 2011;26(4):183-92
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Singh OP, Rout JK, Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(7):1202-7
   PubMed Web of Science ®Google Scholar
• Spelman LM, Walsh PI, Sharifi N, Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007;24(5):481-5
   PubMed Web of Science ®Google Scholar
• Venkatasubramanian G, Chittiprol S, Neelakantachar N, Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007;164(10):1557-60
   PubMed Web of Science ®Google Scholar
• Arranz B, Rosel P, Ramirez N, Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004;65(10):1335-42
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Yao ZJ, Liu W, Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62
   PubMed Web of Science ®Google Scholar
• Gallagher P, Watson S, Smith MS, Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res 2007;90(1-3):258-65
   PubMed Web of Science ®Google Scholar
• Steen NE, Lorentzen S, Barrett EA, Sex-specific cortisol levels in bipolar disorder and schizophrenia during mental challenge–relationship to clinical characteristics and medication. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(4):1100-7
   PubMed Web of Science ®Google Scholar
• Myin-Germeys I, Peeters F, Havermans R, Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study. Acta Psychiatr Scand 2003;107(2):124-31
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Wu GY, BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008;33(9):2200-5
   PubMed Web of Science ®Google Scholar
• Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70(7):1041-50
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Copeland PM, Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62(1):19-28
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R, Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59(4):337-45
   PubMed Web of Science ®Google Scholar
• Bond DJ, Kauer-Sant'Anna M, Lam RW, Yatham LN. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). J Affect Disord 2010;124(1-2):108-17
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012;38(1):167-77. Epub 2010
   PubMed Web of Science ®Google Scholar
• Cacabelos R, Hashimoto R, Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin Neurosci 2011;65(1):3-19
   PubMed Web of Science ®Google Scholar
• Bai YM, Chen TT, Liou YJ, Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res 2011;125(2-3):179-86
   PubMed Web of Science ®Google Scholar
• Liou YJ, Bai YM, Lin E, Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J 2012;12(1):54-61
   PubMed Web of Science ®Google Scholar